UnitedHealth Group (UNH) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
1 Dec, 2025Executive summary
Annual meeting scheduled for June 2, 2025, with virtual attendance available for shareholders.
Shareholders of record as of April 4, 2025, are eligible to vote on key proposals.
Voting can be completed online, by phone, or by email, with confirmation available post-submission.
Voting matters and shareholder proposals
Election of ten directors is on the agenda, with board recommending a vote for all nominees.
Advisory vote on executive compensation is recommended for approval by the board.
Ratification of Deloitte & Touche LLP as independent auditor for 2025 is recommended for approval.
Shareholder proposal on excessive golden parachutes is opposed by the board.
Board of directors and corporate governance
Ten director nominees are listed, including individuals with diverse backgrounds and expertise.
Latest events from UnitedHealth Group
- Q2 2026 revenue reached $112B, EPS $6.38, and guidance was raised on strong earnings and reforms.UNH
Q2 2026 - Director elections, executive pay, and auditor ratified; independent chair proposal failed.UNH
AGM 2026 - Performance award goals and results for executives will be disclosed after 2026-2028.UNH
Proxy filing - AI-driven growth, transparency, and operational efficiency are central to future performance.UNH
Bank of America Global Healthcare Conference 2026 - Board refreshment, AI investment, and executive pay changes highlight a focus on modernization and accountability.UNH
Proxy filing - Q1 2026 revenue up 2% to $111.7B, adjusted EPS $7.23, outlook raised above $18.25.UNH
Q1 2026 - 2026 targets >8.6% EPS growth, margin expansion, and operational discipline amid membership declines.UNH
Q4 2025 - Q2 2025 revenue up 13%, but margins fell on higher medical costs and funding pressures.UNH
Q2 2025 - AI-driven value-based care and consumer focus fuel growth despite funding pressures.UNH
Investor Day 2024 - Hemsley returns as CEO; 2025 outlook suspended, margin recovery and growth targeted for 2026.UNH
Investor Update